MTOR and prostate carcinoma: In a further report, Zhang and co-workers at Wyeth outlined the discovery of a novel class of 5-ureidobenzofuran-3-one indoles also displaying potent p110α/mTOR activity, exemplified by 46, which displayed very high biochemical activity (IC50 = 0.2nM and 0.3nM against p110α and mTOR respectively) with concomitant in vitro tumour cell growth inhibition (GI50 for inhibition of the growth of PC3 prostate cancer cells = 10nM).